OptiNose is a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat and allergy specialists. Co.'s commercial product, XHANCE® (fluticasone propionate) nasal spray is a therapeutic utilizing its proprietary Exhalation Delivery System (EDS®) for the treatment of chronic rhinosinusitis with nasal polyps and. Co.'s solutions also include EDS, which enables the development of drug-device combination products intended for self-administration. Co. has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to provide drug deposition. The OPTN stock yearly return is shown above.
The yearly return on the OPTN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OPTN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|